166 related articles for article (PubMed ID: 30972150)
1. The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab.
Brixner D; Oderda G; Biskupiak J; Burgoyne DS; Avey SG; Feldman SR
Am Health Drug Benefits; 2019 Feb; 12(1):22-26. PubMed ID: 30972150
[TBL] [Abstract][Full Text] [Related]
2. The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans.
Feldman SR; Wu JJ; Rastogi S; Menges B; Lingohr-Smith M; Lin J
J Med Econ; 2018 May; 21(5):537-541. PubMed ID: 29357713
[TBL] [Abstract][Full Text] [Related]
3. Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
Wade R; Grosso A; South E; Rothery C; Saramago P; Schmitt L; Wright K; Palmer S
Pharmacoeconomics; 2019 Feb; 37(2):131-139. PubMed ID: 30112635
[TBL] [Abstract][Full Text] [Related]
4. Brodalumab for Plaque Psoriasis: A Canadian Real-World Experience at 2-Years Post-Launch.
Gaudet V; Yap B; Hassan S; Barbeau M
J Cutan Med Surg; 2023; 27(3):226-235. PubMed ID: 37083148
[TBL] [Abstract][Full Text] [Related]
5. Methods for the comparative evaluation of pharmaceuticals.
Zentner A; Velasco-Garrido M; Busse R
GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
[TBL] [Abstract][Full Text] [Related]
6. Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-to-Severe Psoriasis in the United States.
Feldman SR; Rastogi S; Lin J
Dermatol Ther (Heidelb); 2018 Sep; 8(3):441-453. PubMed ID: 30006866
[TBL] [Abstract][Full Text] [Related]
7. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
8. Illustrating Emerging Good Practices for Quantitative Benefit-Risk Assessment: A Hypothetical Case Study of Systemic Biologic Treatments for Plaque Psoriasis.
Lackey LG; Ng X; Veldwijk J; Thokala P; Levitan B; Payne K; Ho M; Tervonen T
Value Health; 2023 Apr; 26(4):519-527. PubMed ID: 36764517
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States.
Wu JJ; Feldman SR; Rastogi S; Menges B; Lingohr-Smith M; Lin J
J Dermatolog Treat; 2018 Dec; 29(8):769-774. PubMed ID: 29658383
[TBL] [Abstract][Full Text] [Related]
10. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.
Connock M; Burls A; Frew E; Fry-Smith A; Juarez-Garcia A; McCabe C; Wailoo A; Abrams K; Cooper N; Sutton A; O'Hagan A; Moore D
Health Technol Assess; 2006 Jul; 10(24):iii-iv, ix-136. PubMed ID: 16796930
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of cancer drugs: Comparative analysis of the United States and England.
Cherla A; Renwick M; Jha A; Mossialos E
EClinicalMedicine; 2020 Dec; 29-30():100625. PubMed ID: 33437948
[TBL] [Abstract][Full Text] [Related]
12. Modeling the optimal sequence of biologic therapies in plaque psoriasis in Spain.
Egeberg A; Danø A; Pedersen MH; Sohrt A; Borg E; Notario J
J Med Econ; 2021; 24(1):1134-1142. PubMed ID: 34415224
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy.
Roman M; Chiu MW
Drug Des Devel Ther; 2017; 11():2065-2075. PubMed ID: 28744098
[TBL] [Abstract][Full Text] [Related]
14. Is the price right? Paying for value today to get more value tomorrow.
Ramagopalan SV; Diaz J; Mitchell G; Garrison LP; Kolchinsky P
BMC Med; 2024 Jan; 22(1):45. PubMed ID: 38287326
[TBL] [Abstract][Full Text] [Related]
15. Medicaid Formulary Decisions and the Institute for Clinical and Economic Review: Abandoning Pseudoscience in Imaginary Pharmaceutical Pricing Claims.
Langley PC
Innov Pharm; 2021; 12(1):. PubMed ID: 34007677
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Loos AM; Liu S; Segel C; Ollendorf DA; Pearson SD; Linder JA
J Am Acad Dermatol; 2018 Jul; 79(1):135-144.e7. PubMed ID: 29438757
[TBL] [Abstract][Full Text] [Related]
17. European perspective on the costs and cost-effectiveness of cancer therapies.
Drummond MF; Mason AR
J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
[TBL] [Abstract][Full Text] [Related]
18. Estimation of Value-Based Price for 48 High-Technology Medical Devices.
Hyeraci G; Trippoli S; Rivano M; Messori A
Cureus; 2023 Jun; 15(6):e39934. PubMed ID: 37287820
[TBL] [Abstract][Full Text] [Related]
19. An Economic Analysis of the Impact of Homecare Drug Administration for Biologic Interventions Available for Plaque Psoriasis in the UK.
Green W; Stork R; Blanque AP; Nadeem A
Dermatol Ther (Heidelb); 2021 Jul; ():1-8. PubMed ID: 34316432
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
